Biontech to avoid big acquisitions despite billions on the bottom line
Although the pandemic proved very prosperous for Biontech, giving the company new means in the shape of billion-euro profits, it won’t be spending its wealth on any big acquisitions, but instead smaller purchases and partnerships.
by ulrich quistgaard, translated by daniel pedersen
Times have changed for German Biontech, which became very wealthy from sales of its vaccines during the Covid-19 pandemic.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab loses royalties case against Janssen
For subscribers
